
Origin Investment Corp I Announces Closing of $60,000,000 Initial Public Offering
The Company intends to use the net proceeds from the offering, and the simultaneous private placement of units, to pursue and consummate a business combination with one or more businesses.
ThinkEquity acted as the sole book-running manager for the offering.
A registration statement on Form S-1 (File No. 333-284189) relating to the units was filed with the Securities and Exchange Commission ('SEC') and became effective on July 1, 2025. This offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Origin Investment Corp I
The Company is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. While the Company will not limit its search for a target company to any particular business segment, the Company intends to focus its search for a target business in Asia. However, the Company will not consummate its initial business combination with an entity or business in China or with China operations consolidated through a variable interest entity structure.
Forward-Looking Statements
This press release contains statements that constitute 'forward-looking statements,' including with respect to the IPO, the anticipated use of the net proceeds thereof and search for an initial business combination. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus for the IPO filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Edward Chang, CEO+65 7825-5768
[email protected]

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Raymond James Starts Coverage of Republic Bancorp (RBCAA) Stock with a Market Perform
Republic Bancorp, Inc. (NASDAQ:RBCAA) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 27, Raymond James began coverage of the company's stock with a 'Market Perform' rating and no price target, as reported by The Fly. As per the firm, the company is positioned for incremental growth over the upcoming years despite near-term EPS growth headwinds from lower income from the Tax Refund Solutions segment and modest NIM pressure. The analyst opines that the bank has been strategic in making itself a commercially focused community bank, catering to business and retail customers. A customer walking into a bank branch, expressing the convenience of consumer banking services. The firm also noted Republic Bancorp, Inc. (NASDAQ:RBCAA)'s consistent growth, superior capital levels, and improved profitability. Overall, the firm opines that the risk/reward profile for Republic Bancorp, Inc. (NASDAQ:RBCAA)'s stock remains balanced. The company's Tax Refund Solutions segment saw net income of $19.6 million during Q1 2025 as compared to net income of $8.8 million in Q1 2024. The rise was mainly aided by a positive $10.3 million decrease in the estimated Provision for RAs and Early Season RAs versus Q1 2024, and a 30% rise in the average per-unit profitability for Refund Transfers. While we acknowledge the potential of RBCAA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RBCAA and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US FDA approved Dupixent® (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP). The approval for bullous pemphigoid brings a novel treatment approach to patients and their caregivers. Also, this approval extends the ability of Dupixent to transform treatment paradigms for people who live with a variety of diseases with underlying type 2 inflammation, from common conditions such as asthma and atopic dermatitis, to rarer ones, including eosinophilic esophagitis and prurigo nodularis, and now including bullous pemphigoid. A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality. Dupixent demonstrated the potential to improve the most challenging effects of bullous pemphigoid, while, at the same time, supporting some patients in achieving sustained disease remission as well as decreased oral corticosteroid use. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted that the approval also reinforced the demonstrated safety profile of Dupixent in a broad age range of patients, from infants to elderly people, and throughout dermatological, respiratory, and gastrointestinal diseases. The FDA approval was on the basis of data from the pivotal ADEPT Phase 2/3 trial, which evaluated the efficacy and safety of Dupixent as compared to placebo in adults with moderate-to-severe BP. While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Despite all the drama, trade uncertainty hasn't really hurt economic growth, Goldman Sachs says
President Donald Trump's policies may have disrupted trade, but not global economic activity. Investment, employment, and spending remain strong despite initial fears of a slowdown, wrote Goldman Sachs. Growth forecasts for this year have actually improved from earlier, more pessimistic calls. President Donald Trump's new policies may be upending the global trade order, but so far, they're not hitting the economy hard, wrote Goldman Sachs analysts. "There are very few signs that uncertainty is taking a toll on activity," analysts at Goldman Sachs wrote in a Thursday note. Even though the analysts had expected Trump's second term to slow economic activity, the numbers tell a different story. Since late 2024, investment, factory hiring, consumer spending, and broader economic activity have all stayed resilient across major developed and emerging markets. In fact, growth forecasts for both the second quarter and this full year have actually improved from earlier, more pessimistic calls. The analysts pointed out that in most economies, trade-exposed investment accounts for a small share of GDP, so the impact may just be "too small to see." New factory investment, especially in emerging markets, has dipped, but this accounts for just 0.2 to 0.3 percentage points of GDP in major economies. The analysts also wrote that uncertainty usually bites hardest when financial conditions tighten. But global liquidity has actually improved since the start of the year, making it easier for businesses to borrow money and invest. Meanwhile, activity and investment expectations that dipped in April — which coincided with Trump's "Liberation Day" announcement — have already bounced back on improved tariff news. "As such, while we continue to expect that tariffs will slow activity later this year, we expect this will be mostly driven by the direct impacts of tariffs rather than uncertainty around trade policy," they added. Goldman's report came as the US posted better-than-expected employment data in June. The economy added 147,000 jobs, and unemployment fell from 4.2% to 4.1%. Investor sentiment is upbeat, with the S&P 500 and the Nasdaq at record highs. To be sure, trade policy uncertainty remains high by historical standards, with Goldman's uncertainty index spiking after Trump's election. But that uncertainty has eased in recent months as Trump negotiates new trade deals. Some businesses did rush to ship goods to the US ahead of potential tariffs, a phenomenon known as "front-loading," which may have helped mask some issues. But even after controlling for that, Goldman analysts found little evidence of an "uncertainty drag" on growth. There were also few differences between economic activities in countries that did and didn't boost exports to the US this spring. "The uncertainty drag, therefore, appears smaller than feared," they wrote. Read the original article on Business Insider Sign in to access your portfolio